Patent · US Active

HCV E1 comprising specific disulfide bridges

US7413741B2 · kind B2 · utility

2Cited by

2References

9Claims

0Family size

Assignee

Innogenetics N.V. · BE

Inventors

Stany Depraetere · Oudenaarde, BE
Erik Depla · Laarne, BE
Gert Verheyden · Evergem, BE
Alfons Bosman · Opwijk, BE

Key dates

Filing date	Mar 8, 2005
Grant date	Aug 19, 2008
Priority date	—
Expiry date	Mar 14, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2770/24222
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to recombinantly or synthetically produced HCV E1 envelope proteins or parts thereof comprising disulfides between specific cysteine residues. The invention further relates to viral-like particles and compositions comprising said HCV E1 envelope proteins or parts thereof as well as to methods using said HCV E1 envelope proteins or parts thereof, and to kits comprising said HCV E1 envelope proteins or parts thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.